Cargando…

Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients

Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Bibhuti B, Anton, Kristin, Soares, Nelia, Riojas, Susan, Mcdermott, Jodi, Knox, Leah, Daneman, Susan, Puente, Bao N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024571/
https://www.ncbi.nlm.nih.gov/pubmed/29642499
http://dx.doi.org/10.3390/medsci6020030
_version_ 1783336084531314688
author Das, Bibhuti B
Anton, Kristin
Soares, Nelia
Riojas, Susan
Mcdermott, Jodi
Knox, Leah
Daneman, Susan
Puente, Bao N
author_facet Das, Bibhuti B
Anton, Kristin
Soares, Nelia
Riojas, Susan
Mcdermott, Jodi
Knox, Leah
Daneman, Susan
Puente, Bao N
author_sort Das, Bibhuti B
collection PubMed
description Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to report our experience with cimetidine in the treatment of cutaneous warts in pediatric heart transplant recipients. Methods and Results: This was a retrospective observational study. A total of 8 pediatric heart transplant recipients diagnosed with multiple recalcitrant warts were the subject of the study. All patients were treated with cimetidine (30–40 mg/kg/day) in two divided doses for 3 to 6 month durations. All patients had complete resolution of their lesions except 1 patient who had no clinical improvement. Of these 8 patients, one had recurrence of warts at one year follow-up, which resolved with restarting cimetidine therapy. One patient who had only 3 months of cimetidine therapy had immediate relapse after cimetidine was stopped. None of them had significant change in their tacrolimus trough, serum creatinine, and alanine transaminase levels. No adverse events were reported except one patient experienced mild gynecomastia. Conclusion: Cimetidine can be a safe and alternative treatment option for multiple warts in pediatric heart transplant recipients.
format Online
Article
Text
id pubmed-6024571
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60245712018-07-05 Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients Das, Bibhuti B Anton, Kristin Soares, Nelia Riojas, Susan Mcdermott, Jodi Knox, Leah Daneman, Susan Puente, Bao N Med Sci (Basel) Article Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to report our experience with cimetidine in the treatment of cutaneous warts in pediatric heart transplant recipients. Methods and Results: This was a retrospective observational study. A total of 8 pediatric heart transplant recipients diagnosed with multiple recalcitrant warts were the subject of the study. All patients were treated with cimetidine (30–40 mg/kg/day) in two divided doses for 3 to 6 month durations. All patients had complete resolution of their lesions except 1 patient who had no clinical improvement. Of these 8 patients, one had recurrence of warts at one year follow-up, which resolved with restarting cimetidine therapy. One patient who had only 3 months of cimetidine therapy had immediate relapse after cimetidine was stopped. None of them had significant change in their tacrolimus trough, serum creatinine, and alanine transaminase levels. No adverse events were reported except one patient experienced mild gynecomastia. Conclusion: Cimetidine can be a safe and alternative treatment option for multiple warts in pediatric heart transplant recipients. MDPI 2018-04-08 /pmc/articles/PMC6024571/ /pubmed/29642499 http://dx.doi.org/10.3390/medsci6020030 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Das, Bibhuti B
Anton, Kristin
Soares, Nelia
Riojas, Susan
Mcdermott, Jodi
Knox, Leah
Daneman, Susan
Puente, Bao N
Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
title Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
title_full Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
title_fullStr Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
title_full_unstemmed Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
title_short Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
title_sort cimetidine: a safe treatment option for cutaneous warts in pediatric heart transplant recipients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024571/
https://www.ncbi.nlm.nih.gov/pubmed/29642499
http://dx.doi.org/10.3390/medsci6020030
work_keys_str_mv AT dasbibhutib cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients
AT antonkristin cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients
AT soaresnelia cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients
AT riojassusan cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients
AT mcdermottjodi cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients
AT knoxleah cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients
AT danemansusan cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients
AT puentebaon cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients